CoChat
Sign Up
Cited by 173

Role of the Gut–Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship

Ohtani, Naoko, Kawada, Norifumi·2019·Hepatology Communications
DOI 10.1002/hep4.1331PMC PMC6442695
Open this paper in CoChat — free account

Abstract

The gut and the liver are anatomically and physiologically connected, and this “gut–liver axis” exerts various influences on liver pathology. The gut microbiota consists of various microorganisms that normally coexist in the human gut and have a role of maintaining the homeostasis of the host. However, once homeostasis is disturbed, metabolites and components derived from the gut microbiota translocate to the liver and induce pathologic effects in the liver. In this review, we introduce and discuss the mechanisms of liver inflammation, fibrosis, and cancer that are influenced by gut microbial components and metabolites; we include recent advances in molecular‐based therapeutics and novel mechanistic findings associated with the gut–liver axis and gut microbiota.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep4.1331

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 96

  1. [1]Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut‐liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018; 15: 397‐ 411. 29748586 PMC6319369
  2. [3]Seo YS, Shah VH. The role of gut‐liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 2012; 18: 337‐ 346. 23323248 PMC3540369
  3. [4]Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut‐liver axis in liver disease. J Hepatol 2017; 67: 1084‐ 1103. Erratum. J Hepatol 2018;68:1336. 28526488
  4. [5]Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short‐chain fatty acids, and host metabolic regulation. Nutrients 2015; 7: 2839‐ 2849. 25875123 PMC4425176
  5. [6]Burcelin R, Serino M, Chabo C, Blasco‐Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol 2011; 48: 257‐ 273. 21964884 PMC3224226
  6. [8]Dzutsev A, Badger JH, Perez‐Chanona E, Roy S, Salcedo R, Smith CK, et al. Microbes and cancer. Annu Rev Immunol 2017; 35: 199‐ 228. 28142322
  7. [10]Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, et al. Short‐chain fatty acids and ketones directly regulate sympathetic nervous system via G protein‐coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 2011; 108: 8030‐ 8035. 21518883 PMC3093469
  8. [11]Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF‐beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324‐ 1332. 17952090
  9. [13]Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, et al. Gut microbiota promotes obesity‐associated liver cancer through PGE2‐mediated suppression of antitumor immunity. Cancer Discov 2017; 7: 522‐ 538. 28202625
  10. [14]Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. J Exp Med 2018; 215: 383‐ 396. 29339445 PMC5789421
  11. [15]Payne CM, Weber C, Crowley‐Skillicorn C, Dvorak K, Bernstein H, Bernstein C, et al. Deoxycholate induces mitochondrial oxidative stress and activates NF‐kappaB through multiple mechanisms in HCT‐116 colon epithelial cells. Carcinogenesis 2007; 28: 215‐ 222. 16887864
  12. [16]Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2017; 14: 397‐ 411. 28487545
  13. [17]Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J 1991; 5: 271‐ 277. 2001786
  14. [18]Wake K. Perisinusoidal stellate cells (fat‐storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A‐storing cells in extrahepatic organs. Int Rev Cytol 1980; 66: 303‐ 353. 6993411
  15. [19]Moriwaki H, Blaner WS, Piantedosi R, Goodman DS. Effects of dietary retinoid and triglyceride on the lipid composition of rat liver stellate cells and stellate cell lipid droplets. J Lipid Res 1988; 29: 1523‐ 1534. 3241127
  16. [20]Kawada N, Tran‐Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993; 213: 815‐ 823. 7682947
  17. [21]Pinzani M, Failli P, Ruocco C, Casini A, Milani S, Baldi E, et al. Fat‐storing cells as liver‐specific pericytes. Spatial dynamics of agonist‐stimulated intracellular calcium transients. J Clin Invest 1992; 90: 642‐ 646. 1644929 PMC443145
  18. [22]Sugimoto H, Makino M, Sawai H, Kawada N, Yoshizato K, Shiro Y. Structural basis of human cytoglobin for ligand binding. J Mol Biol 2004; 339: 873‐ 885. 15165856
  19. [23]She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 2005; 280: 4959‐ 4967. 15537655
  20. [24]Wandzioch E, Kolterud A, Jacobsson M, Friedman SL, Carlsson L. Lhx2‐/‐ mice develop liver fibrosis. Proc Natl Acad Sci U S A 2004; 101: 16549‐ 16554. 15536133 PMC526277
  21. [25]Koo JH, Lee HJ, Kim W, Kim SG. Endoplasmic reticulum stress in hepatic stellate cells promotes liver fibrosis via PERK‐mediated degradation of HNRNPA1 and up‐regulation of SMAD2. Gastroenterology 2016; 150: 181‐ 193.e188. 26435271
  22. [26]Kawasaki K, Ushioda R, Ito S, Ikeda K, Masago Y, Nagata K. Deletion of the collagen‐specific molecular chaperone Hsp47 causes endoplasmic reticulum stress‐mediated apoptosis of hepatic stellate cells. J Biol Chem 2015; 290: 3639‐ 3646. 25525267 PMC4319029
  23. [28]Kim KH, Chen CC, Monzon RI, Lau LF. Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol 2013; 33: 2078‐ 2090. 23508104 PMC3647960
  24. [29]Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012; 109: 9448‐ 9453. 22566629 PMC3386114
  25. [31]Sato‐Matsubara M, Matsubara T, Daikoku A, Okina Y, Longato L, Rombouts K, et al. Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling. J Biol Chem 2017; 292: 18961‐ 18972. 28916723 PMC5706471
  26. [33]Mogler C, Konig C, Wieland M, Runge A, Besemfelder E, Komljenovic D, et al. Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin. EMBO Mol Med 2017; 9: 741‐ 749. 28373218 PMC5452049
  27. [34]Duran A, Hernandez ED, Reina‐Campos M, Castilla EA, Subramaniam S, Raghunandan S, et al. p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer. Cancer Cell 2016; 30: 595‐ 609. 27728806 PMC5081228
  28. [35]le Thuy TT, Morita T, Yoshida K, Wakasa K, Iizuka M, Ogawa T, et al. Promotion of liver and lung tumorigenesis in DEN‐treated cytoglobin‐deficient mice. Am J Pathol 2011; 179: 1050‐ 1060. 21684245 PMC3157247
  29. [36]le Thuy TT, Matsumoto Y, Thuy TT, Hai H, Suoh M, Urahara Y, et al. Cytoglobin deficiency promotes liver cancer development from hepatosteatosis through activation of the oxidative stress pathway. Am J Pathol 2015; 185: 1045‐ 1060. 25665792
  30. [39]Smith K. Liver disease: Kupffer cells regulate the progression of ALD and NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 503. 23877532
  31. [40]Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL‐1 receptor antagonist ameliorates inflammasome‐dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122: 3476‐ 3489. 22945633 PMC3461900
  32. [41]Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219‐ 246. 20148674
  33. [42]Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 2017; 17: 306‐ 321. 28317925
  34. [43]Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin‐18 in inflammatory liver diseases. Immunol Rev 2000; 174: 192‐ 209. 10807517
  35. [44]Kazankov K, Jorgensen SMD, Thomsen KL, Moller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2018; 10.1038/s41575-018-0082-x. 30482910 · DOI · Paper page
  36. [45]Ide M, Kuwamura M, Kotani T, Sawamoto O, Yamate J. Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide‐induced rat hepatic lesions. J Comp Pathol 2005; 133: 92‐ 102. 15964588
  37. [46]Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56‐ 65. 15630444 PMC539199
  38. [47]Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009; 50: 261‐ 274. 19554540
  39. [48]Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS, et al. Scar‐associated macrophages are a major source of hepatic matrix metalloproteinase‐13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007; 178: 5288‐ 5295. 17404313
  40. [49]Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly‐6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012; 109: E3186‐ E3195. 23100531 PMC3503234
  41. [51]Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J, et al. Granulocyte colony‐stimulating factor and autologous CD133‐positive stem‐cell therapy in liver cirrhosis (REALISTIC): an open‐label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol 2018; 3: 25‐ 36. 29127060 PMC5738975
  42. [52]Ambade A, Lowe P, Kodys K, Catalano D, Gyongyosi B, Cho Y, et al. Pharmacological inhibition of CCR52/5 signaling prevents and reverses alcohol‐induced liver damage, steatosis and inflammation in mice. Hepatology 2018; 10.1002/hep.30249. PMC6393202 30179264 · DOI
  43. [53]Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 2018; 67: 1270‐ 1283. 28940700
  44. [55]Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, Yanai A, et al. Deletion of apoptosis signal‐regulating kinase 1 attenuates acetaminophen‐induced liver injury by inhibiting c‐Jun N‐terminal kinase activation. Gastroenterology 2008; 135: 1311‐ 1321. 18700144
  45. [56]Zhang P, Wang PX, Zhao LP, Zhang X, Ji YX, Zhang XJ, et al. The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. Nat Med 2018; 24: 84‐ 94. 29227477
  46. [57]Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al.; GS‐US‐384‐1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 2017; 10.1002/hep.29514. Erratum. In: Hepatology 2018;67:2063. PMC5814892 28892558 · DOI · Paper page
  47. [59]Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014; 513: 59‐ 64. 25079328
  48. [60]Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation. Nature 2015; 525: E1‐ E2. 26381988 PMC4617624
  49. [62]Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll‐like receptor 4 (TLR4) antagonists. Biotechnol Adv 2012; 30: 251‐ 260. 21664961
  50. [63]Fukui H. Gut Microbiome‐based Therapeutics in liver cirrhosis: basic consideration for the next step. J Clin Transl Hepatol 2017; 5: 249‐ 260. 28936406 PMC5606971
  51. [64]Stenman LK, Holma R, Eggert A, Korpela R. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol 2013; 304: G227‐ G234. 23203158
  52. [65]Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949‐ 955. 23333527 PMC3936319
  53. [66]Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 2016; 151: 733‐ 746.e712. 27342212 PMC5037035
  54. [67]Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2609‐ 2618. 22690069 PMC3369997
  55. [69]Acharya C, Bajaj JS. Current management of hepatic encephalopathy. Am J Gastroenterol 2018; 113: 1600‐ 1612. 30002466
  56. [70]Swaminathan M, Ellul MA, Cross TJ. Hepatic encephalopathy: current challenges and future prospects. Hepat Med 2018; 10: 1‐ 11. 29606895 PMC5868572
  57. [71]Mancini A, Campagna F, Amodio P, Tuohy KM. Gut: liver: brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct 2018; 9: 1373‐ 1388. 29485654
  58. [72]Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, et al. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis 2018; 67: 869‐ 877. 29718124
  59. [73]Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology 2017; 152: 134‐ 141. 27639806
  60. [76]Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39: 1276‐ 1285. 24738701 PMC4046270
  61. [77]Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 2017; 67: 302‐ 309. 28336466
  62. [78]Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A nationwide survey on non‐B, non‐C hepatocellular carcinoma in Japan: 2011‐2015 update. J Gastroenterol 2018; 10.1007/s00535-018-1532-5. PMC6437291 30498904 · DOI
  63. [79]Mak LY, Cruz‐Ramon V, Chinchilla‐Lopez P, Torres HA, LoConte NK, Rice JP, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2018; 262‐ 279. 30231359
  64. [80]Arrese M, Feldstein AE. NASH‐related cirrhosis: an occult liver disease burden. Hepatol Commun 2017; 1: 84‐ 86. 29335681 PMC5721433
  65. [81]Friedman SL, Neuschwander‐Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908‐ 922. 29967350 PMC6553468
  66. [82]Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non‐alcoholic fatty liver disease. Gut 2017; 66: 180‐ 190. 27646933
  67. [83]Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2017; 33: 134‐ 141. 28346237 PMC5491795
  68. [84]Neuschwander‐Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial. Lancet 2015; 385: 956‐ 965. 25468160 PMC4447192
  69. [85]Carr RM, Reid AE. FXR agonists as therapeutic agents for non‐alcoholic fatty liver disease. Curr Atheroscler Rep 2015; 17: 500. 25690590
  70. [86]Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018; 53: 362‐ 376. 29247356 PMC5847174
  71. [87]Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids 2014; 86: 62‐ 68. 24819989 PMC4073476
  72. [89]Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 2013; 4: 382‐ 387. 23851335 PMC3839982
  73. [90]Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front Neurosci 2017; 11: 617. 29163019 PMC5681992
  74. [91]Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72: 137‐ 174. 12543708
  75. [93]Hofmann AF. The enterohepatic circulation of bile acids in man. Adv Intern Med 1976; 21: 501‐ 534. 766594
  76. [94]Mok HY, Von Bergmann K, Grundy SM. Regulation of pool size of bile acids in man. Gastroenterology 1977; 73: 684‐ 690. 892372
  77. [95]Al‐Khaifi A, Rudling M, Angelin B. An FXR agonist reduces bile acid synthesis independently of increases in FGF19 in healthy volunteers. Gastroenterology 2018; 155: 1012‐ 1016. 29928896
  78. [96]Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010; 8: e005. 21383957 PMC3049226
  79. [97]Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther 2017; 179: 142‐ 157. 28546081 PMC6659998
  80. [99]Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 2012; 28: 159‐ 165. 22134222 PMC3601486
  81. [100]Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57‐ 63. 21475195 PMC3086762
  82. [102]He X, Ji G, Jia W, Li H. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanism and application of metabolomics. Int J Mol Sci 2016; 17: 300. 26999104 PMC4813164
  83. [103]Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab 2017; 26: 394‐ 406.e396. 28768177 PMC5603267
  84. [104]Minami S, Miura K, Ishioka M, Morimoto N, Isoda N, Yamamoto H, et al. Homocysteine supplementation ameliorates steatohepatitis induced by a choline‐deficient diet in mice. Hepatol Res 2019; 49: 189‐ 200. 30048033
  85. [105]Honda T, Ishigami M, Luo F, Lingyun M, Ishizu Y, Kuzuya T, et al. Branched‐chain amino acids alleviate hepatic steatosis and liver injury in choline‐deficient high‐fat diet induced NASH mice. Metabolism 2017; 69: 177‐ 187. 28285648
  86. [106]Kishino S, Takeuchi M, Park SB, Hirata A, Kitamura N, Kunisawa J, et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc Natl Acad Sci U S A 2013; 110: 17808‐ 17813. 24127592 PMC3816446
  87. [107]Miyamoto J, Mizukure T, Park SB, Kishino S, Kimura I, Hirano K, et al. A gut microbial metabolite of linoleic acid, 10‐hydroxy‐cis‐12‐octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40‐MEK‐ERK pathway. J Biol Chem 2015; 290: 2902‐ 2918. 25505251 PMC4317025
  88. [108]Nanthirudjanar T, Furumoto H, Zheng J, Kim YI, Goto T, Takahashi N, et al. Gut microbial fatty acid metabolites reduce triacylglycerol levels in hepatocytes. Lipids 2015; 50: 1093‐ 1102. 26399511
  89. [109]Ferreira DM, Afonso MB, Rodrigues PM, Simao AL, Pereira DM, Borralho PM, et al. c‐Jun N‐terminal kinase 1/c‐Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol 2014; 34: 1100‐ 1120. 24421392 PMC3958031
  90. [110]Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, et al. Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 2018; 48: 1109‐ 1116. 30288767
  91. [111]Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, et al. Hepatocellular carcinoma arising from non‐cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190‐ 1194. 19672551
  92. [113]Takuma Y, Nouso K. Nonalcoholic steatohepatitis‐associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010; 16: 1436‐ 1441. 20333782 PMC2846247
  93. [114]Yamada S, Takashina Y, Watanabe M, Nagamine R, Saito Y, Kamada N, et al. Bile acid metabolism regulated by the gut microbiota promotes non‐alcoholic steatohepatitis‐associated hepatocellular carcinoma in mice. Oncotarget 2018; 9: 9925‐ 9939. 29515780 PMC5839411
  94. [115]Singh V, Yeoh BS, Chassaing B, Xiao X, Saha P, Aguilera Olvera R, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell 2018; 175: 679‐ 694.e622. 30340040 PMC6232850
  95. [116]Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, et al. Gut microbiome‐mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018; 360. PMC6407885 29798856
  96. [122]Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res 2018; 37: 110. 29843754 PMC5975687

Cited by

Sorted by citations

Authors
Ohtani, N., & Kawada, N.
Affiliations
  • Department of Pathophysiology,Osaka City University, Graduate School of Medicine,Osaka,Japan
  • Department of Hepatology,Osaka City University, Graduate School of Medicine,Osaka,Japan
Venue
Hepatology Communications
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2019-03-01
Volume
3
Issue
4
Pages
456-470
ISSN
2471-254X
DOI
10.1002/hep4.1331
PMC
PMC6442695
Cited by
173
References
26
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review